Oxygen Therapy: When It Is Needed and How It Works

Oxygen therapy is a medical intervention that delivers supplemental oxygen to patients whose arterial blood oxygen levels fall below clinically acceptable thresholds. It spans acute hospital settings, long-term home use, and palliative care, making it one of the most widely applied respiratory treatments in modern medicine. Understanding when oxygen therapy is indicated — and how different delivery systems function — is foundational to managing conditions covered across the pulmonary medicine resource index.

Definition and scope

Oxygen therapy refers to the administration of oxygen at concentrations above the approximately 21% found in ambient air, with the goal of correcting or preventing hypoxemia — abnormally low oxygen tension in arterial blood. The Centers for Medicare & Medicaid Services (CMS) formally recognizes supplemental oxygen as durable medical equipment (DME) under Medicare Part B, establishing coverage criteria tied to documented arterial oxygen partial pressure (PaO₂) or oxygen saturation (SpO₂) values (CMS DME Coverage Guidelines).

Clinically, oxygen therapy is classified along two primary axes:

1. Acute versus long-term therapy — Acute oxygen is administered in emergencies or inpatient settings; long-term oxygen therapy (LTOT) is prescribed for chronic conditions requiring continuous or nocturnal supplementation.
2. Low-flow versus high-flow systems — Low-flow devices (nasal cannulas, simple masks) deliver variable inspired oxygen fractions (FiO₂) depending on patient breathing patterns; high-flow systems (Venturi masks, heated high-flow nasal cannulas) deliver precise, controlled FiO₂ values regardless of ventilatory rate.

The regulatory context for pulmonary medicine outlines how federal standards govern prescribing thresholds, equipment certification, and home oxygen supplier requirements under CMS and the Joint Commission.

How it works

Atmospheric air contains approximately 21% oxygen by volume. When disease impairs alveolar gas exchange — through fluid accumulation, airway obstruction, or parenchymal destruction — the partial pressure of oxygen in arterial blood (PaO₂) falls. Supplemental oxygen raises the fraction of inspired oxygen, increasing the driving pressure for diffusion across the alveolar-capillary membrane and restoring arterial oxygen saturation toward normal range.

The physiologic target in most clinical protocols is an SpO₂ of 94–98% in the general adult population, or 88–92% in patients with chronic hypercapnic conditions such as COPD, where hypoxic drive is a documented management consideration. These targets align with guidance published by the British Thoracic Society (BTS) in its Emergency Oxygen guidelines (BTS Emergency Oxygen Guideline, 2017).

Delivery mechanisms differ substantially in their ability to achieve these targets:

High-flow nasal cannula (HFNC) systems also deliver warmed, humidified gas and generate a small degree of positive airway pressure, which can improve oxygenation in patients with acute hypoxemic respiratory failure beyond what FiO₂ alone explains.

Arterial blood gas testing and pulse oximetry are the primary measurement tools used to assess oxygenation status and guide titration of supplemental flow rates.

Common scenarios

Oxygen therapy is indicated across a wide range of pulmonary and systemic conditions. The following structured breakdown reflects the major clinical categories:

1. Acute hypoxemia from respiratory infection — Pneumonia is among the most common acute indications; SpO₂ below 94% in adults with community-acquired pneumonia typically triggers supplemental oxygen in emergency department and inpatient protocols.
2. Exacerbations of obstructive lung disease — Acute exacerbations of COPD and severe asthma attacks reduce effective ventilation and gas exchange; controlled low-flow oxygen is titrated carefully to avoid suppressing ventilatory drive in hypercapnic patients.
3. Pulmonary embolism — Obstruction of pulmonary vasculature in pulmonary embolism impairs gas exchange; oxygen therapy is a standard supportive measure alongside anticoagulation.
4. Pulmonary fibrosis — Progressive scarring in pulmonary fibrosis reduces alveolar surface area; LTOT is prescribed when resting, nocturnal, or exertional desaturation meets CMS coverage thresholds.
5. Pulmonary hypertension — In pulmonary hypertension, hypoxia-mediated pulmonary vasoconstriction worsens right heart strain; correcting hypoxemia with supplemental oxygen reduces pulmonary vascular resistance.
6. Palliative dyspnea — Oxygen is used in end-stage disease for symptom relief, though evidence for benefit in non-hypoxemic patients remains limited per the American Thoracic Society (ATS) palliative care guidelines.
7. Sleep-related hypoxemia — Nocturnal oxygen desaturation associated with sleep apnea or obesity hypoventilation may require nocturnal supplemental oxygen when positive airway pressure therapy alone is insufficient.

Patients prescribed home oxygen for any of these conditions benefit from structured education through resources such as using home oxygen and pulmonary rehabilitation.

Decision boundaries

The Medicare LTOT coverage threshold — as established by CMS — requires documented PaO₂ ≤ 55 mmHg or SpO₂ ≤ 88% at rest, or PaO₂ of 56–59 mmHg with evidence of cor pulmonale, erythrocytosis, or clinical deterioration (CMS Local Coverage Determination for Home Oxygen, LCD L33797). Nocturnal-only or exertional-only oxygen may be covered under separate documentation criteria.

The distinction between acute and long-term indication is clinically significant:

• Acute oxygen is titrated to clinical response and discontinued when the underlying cause resolves; prescribing targets are protocol-driven and do not require CMS documentation.
• Long-term oxygen therapy requires formal qualification testing — typically conducted after clinical stabilization, at least 30 days after an acute event — to confirm persistent hypoxemia.

The National Institute for Health and Care Excellence (NICE) in the UK and the ATS in the United States both caution against liberal oxygen prescribing in normoxemic patients, citing evidence that hyperoxia can worsen outcomes in certain conditions including acute myocardial infarction and stroke (ATS Statement on Oxygen Therapy, Am J Respir Crit Care Med).

Safety considerations under home oxygen use include fire risk from oxygen-enriched environments — the U.S. Food and Drug Administration (FDA) regulates home oxygen concentrators and compressed gas equipment as Class II medical devices under 21 CFR Part 880 (FDA Device Classification, 21 CFR Part 880). Patients and caregivers managing home systems should review safety protocols from sources including the National Fire Protection Association (NFPA).

References

• Centers for Medicare & Medicaid Services — DME Home Oxygen Coverage (LCD L33797)
• British Thoracic Society — Emergency Oxygen Guideline (2017)
• American Thoracic Society — ATS Journal of Respiratory and Critical Care Medicine
• National Institute for Health and Care Excellence (NICE) — COPD Guidelines
• U.S. Food and Drug Administration — 21 CFR Part 880, General Hospital and Personal Use Devices
• National Fire Protection Association (NFPA) — Home Medical Oxygen Safety

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)